Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 4072644 | Posterior atlanto-axial subluxation in rheumatoid arthritis. | 1985 Aug | Among 130 patients operated for rheumatoid arthritis of the cervical spine, four patients had the rare condition of posterior subluxation of the atlas. After fusion they were relieved of pain and their neurologic dysfunction improved. | |
| 312949 | Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. | 1979 Jul 6 | The safety and efficacy of influenza vaccination were studied in 32 healthy volunteers and in 62 patients with systemic lupus erythematosus (SLE), rheumatoid arthritis, degenerative joint disease, and other rheumatic diseases. These individuals, none of whom was acutely ill, were examined at the time of immunization and one week, three weeks, and four months later. Flare-ups of rheumatic disease following immunization were infrequent and usually minor. Seroconversion to A/New Jersey/76 developed in 62% to 87% of all individuals and to A/Victoria/75 in 62% to 69%. Antibody responses to A/New Jersey/76 were significantly lower in young patients taking glucocorticoids compared to those not taking glucocorticoids. The antibody responses to A/New Jersey/76 and A/Victoria/75 in patients with SLE were not different from normal responses. Administration of these vaccines was safe in these patients with stable disease and induced antibody responses in most individuals. | |
| 1210106 | [Metabolism of collagen in infectious nonspecific (rheumatoid) polyarthritis]. | 1975 May | Distinct impairments in collagen metabolism were observed in infectious (rheumatoid) polyarthritis. The impairements were manifested as increased excretion of hydroxyproline with urine and increased content of protein bound hydroxyproline in blood plasma and synovial fluid; the impairements increased with an increased in severity and abundance of pathological process in connective tissue. After successful treatment of patients (surgical operation, combined with complex antirheumatic treatment) content of the collagen metabolites was decreased in biological fluids; this decrease was not observed if the inflammatory process in the connective tissue was present. | |
| 913121 | Flurbiprofen in rheumatoid arthritis therapy. | 1977 | Preliminary findings are reported from an open study of 300 mg flurbiprofen daily in 24 patients and from 6 out of 30 patients treated so far in a double-blind crossover comparison of 300 mg flurbiprofen daily and 150 mg indomethacin daily in the treatment of rheumatoid arthritis. The results indicate that flurbiprofen is effective in relieving symptoms and is better tolerated than indomethacin. Using an experimental model in rats to assess the anti-inflammatory activity of flurbiprofen, data suggest that flurbiprofen is unable to prevent an immunological type of inflammation but is capable of modifying the type and extent of cellular infiltration. | |
| 6441248 | The relationship between aurothioglucose- and D-penicillamine-induced proteinuria. | 1984 | We studied patients with rheumatoid arthritis who have been treated with aurothioglucose (Au) and subsequently with D-penicillamine (DP), and who developed drug-induced proteinuria, over a 10-year period. Twelve patients developed Au-induced and 19 DP-induced proteinuria. Of the 12 patients with Au-induced proteinuria, only 2 (17%) developed DP-induced proteinuria, indicating a slightly increased risk as compared with the overall incidence (9.3%) of this reaction in 168 DP-treated patients. In addition, only a minority (2 out of 19, 10.6%) of patients with DP-induced proteinuria had previous Au-induced proteinuria. These data may indicate that different mechanisms are operative in Au and DP-induced proteinuria, as is also suggested by the finding that HLA-DR3 was present more frequently in the latter (50%) than in the former (21%). A history of previous Au-induced proteinuria is insufficient reason to deny these patients the benefits of subsequent treatment with DP. | |
| 6414387 | Gold levels produced by treatment with auranofin and sodium aurothiomalate. | 1983 Oct | Sixty-three patients with rheumatoid arthritis were randomly divided into 3 groups, and treated with either sodium aurothiomalate (Myocrisin), auranofin, or placebo. Gold levels in whole blood, plasma, and haemolysate were measured serially along with clinical and laboratory parameters of efficacy. Auranofin produced a higher ratio of haemolysate to plasma gold than Myocrisin, and it appears that the affinity of the red cell for gold is reduced during therapy with auranofin. Gold levels did not correlate with changes in the pain score, erythrocyte sedimentation rate, and C-reactive protein, nor with the development of toxicity. In the Myocrisin group the haemolysate gold level achieved was dependent on the number of cigarettes smoked. In the auranofin group there was no such correlation, but the haemolysate gold level was higher for smokers than non-smokers. The likely action of gold is discussed. | |
| 133601 | A multicentre controlled trial of the effects of different dosage of gold therapy, followe | 1976 Feb | In a combined clinical trial with gold in patients with rheumatoid arthritis (RA) 95 patients were treated with a high initial dosage of 2,500 mg aurothioglucose in 21 weeks. Afterwards 48 of these patients received a maintenance dosage of gold and 47 patients placebo injections. Another group of 101 patients received 1,000 mg gold in 21 weeks. Finally a maintenance dose of gold was administered to 49 of these patients, to the other 52 patients placebo injections were administered. For the treatment of RA a high dosage of a gold compound offers no advantage over a low dosage. After a high dosage one can expect a significantly higher number of side effects. The development of toxicity does not influence the ultimate results. A second course of gold has hardly any benificial effect. Prolonged administration of gold is usually well-tolerated; whether it has substantial and sustained therapeutic value remains dubious. Progression of radiological abnormalities can be observed at the same moment that signs and other symptoms of the disease show improvement. | |
| 3888863 | Piroxicam versus naproxen in rheumatoid arthritis: a double-blind, cross-over study. | 1985 | Piroxicam 20 mg daily was compared with naproxen 1000 mg daily in a double-blind cross-over study of 24 patients with rheumatoid arthritis. A comparison was also made with the pre-trial medication. The effect of the pre-trial medication, piroxicam and naproxen, were found to be similar. The side-effects of piroxicam and naproxen were similar and mild. | |
| 1257462 | Spontaneous fractures of the olecranon process in rheumatoid arthritis. | 1976 Apr | Spontaneous fractures through the olecranon process occurred in 3 patients with long-standing rheumatoid arthritis. In each case the elbow was severely damaged, particularly in the midportion of the trochlear notch, which was thinned either by erosion or cyst formation. The thin trichlear notch is the weak pivot point of a lever (the olecranon process) which pivots on the distal humerus. Excess stress on the lever, by the action of the triceps on the olecranon process, will produce a fracture at the weakest point: the midtrochlear notch. | |
| 6237051 | Lymphocyte sub-population counts after a single 40 mg administration of piroxicam in 20 pa | 1984 Jun | Patients with active rheumatoid arthritis are characterized by a decrease in the number of circulating T-suppressor lymphocytes (identified by OKT8), resulting in an imbalance between helper (identified by OKT4) and suppressor cells. Piroxicam is a non-steroidal anti-inflammatory agent which modulates lymphocytic functions, especially by reducing the concentration of the rheumatoid factor in vitro and in vivo. A double-blind placebo-controlled study was performed in 20 patients suffering from active RA to investigate the acute effect of a single administration of piroxicam 40 mg on the number of circulating OKT3, T4, T8 and IA1 positive cells. Blood samples were obtained 16 hours before and 0, 2, 6, 8, 24, 48, and 72 h after administration of piroxicam or placebo. There was a significant decrease (P less than 0.05) in T4/T8 cell ratio 48 and 72 h after piroxicam, whereas placebo had no effect. There were no significant changes in absolute numbers of total T-lymphocyte (OKT3 positive cells), T-helper-inducer (OKT4 positive cells) and T-suppressor cytotoxic lymphocytes (OKT8 positive cells). The number of IA1 positive cells (B-cells and activated T-lymphocytes) was significantly higher in the afternoon samples (at 14.00 and 16.00 hours) than in the morning samples (at 08.00 and 10.00 hours) after both placebo and piroxicam administration (P less than 0.05). These data show that piroxicam decreases the T4/T8 cell ratio in active RA, but only 48 h after the first administration.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 107867 | Gold and penicillamine: a proposed mode of action in rheumatoid arthritis, based on synovi | 1978 Dec | Although in common use, there is still controversy as to the way in which gold and penicillamine act in rheumatoid arthritis (RA). In this study, synovial fluids from 4 groups of patients have been compared: (1) RA patients on gold/penicillamine, (2) RA patients on non-steriodal anti-inflammatory drugs (NSAID) only, (3) osteoarthritis patients, and (4) patients with sero-negative arthropathies. The parameters measured were differential agglutination titre (DAT), total haemolytic complement (CH50), total protein, total white cell count, and immunoglobulins. RA patients on gold/penicillamine have lower synovial DAT levels and higher CH50 levels than RA patients on NSAID only, and total and cryoprecipitable IgM levels very close to those found in the sero-negative joint fluids. The non-specific inflammatory parameters, ie, white cell count and total protein are unchanged after good/penicillamine therapy. In a second study, the serum DATs of patients in total remission after gold/penicillamine were compared with similar patients on NSAID only. The DAT falls significantly in the former group (P less than 0.001), but not in the latter suggesting that fall in DAT is a consequence of therapy rather than remission. The parameters altered by gold/penicillamine in the synovial fluid are those that distinguish RA from non-rheumatoid arthropathies suggesting the drug's primary effect is to render the disease sero-negative. The results support the hypothesis that both drugs have a common mode of action based on their active thiol groups, and that the fall in DAT is due to the reduction of the antigenicity of the IgG complexes. | |
| 921001 | Lymphocytes' cytotoxicity towards cells of human lymphoblastoid lines in patients with rhe | 1977 Nov | A research study and discussion of antiinterferon immunoglobulin in the treatment of rheumatoid arthritis and systemic lupus erythematosus, and its possible value in the treatment of allergic diseases, autoimmune diseases and other diseases where it is presumed there may be an autoimmune genesis. | |
| 6857174 | Specific plasma proteins as indices of inflammation during a modified fast in patients wit | 1983 | Fourteen patients with classical rheumatoid arthritis and 7 healthy controls underwent a modified fast, containing diluted fruit and vegetable juices, for a 10-day period. To evaluate the effect of fasting on the inflammatory activity, plasma protein determinations were performed before and on the 10th day of fasting. Both patients and healthy controls developed reduced plasma levels of complement factor 3 (C3), orosomucoid and haptoglobin, although only the decrease in C3 and orosomucoid was greater in the patient group. An unchanged level in plasma of albumin, IgG, IgA, IgM and complement factor 4 was found. We conclude that determination of C3 and orosomucoid in plasma may be useful as indices of inflammation during fasting conditions. | |
| 843119 | Dermatomyositis complicating penicillamine treatment. | 1977 Feb | A case of dermatomyositis developing during the course of treatment with D-penicillamine in a patient with rheumatoid arthritis is described. Complete remission occurred on withdrawal of the drug. Possible alternative diagnoses are discussed. | |
| 378501 | Concentration dependent plasma protein binding of salicylate in rheumatoid patients. | 1979 Mar | Acetylsalicylic acid in daily doses from 3 to 6g was prescribed to 8 patients with rheumatoid arthritis. Various assessments of clinical effect, as well as steady-state plasma concentrations and degree of plasma protein binding, were determined at each dose. The unbound fraction of salicylate increased with the dose, resulting in very high free concentrations of drug in some patients. No statistically significant relationship between total or unbound plasma concentration and the measurements of clinical efficacy were obtained. The marked increase with the dose in unbound salicylate concentration is interpreted as the result of the saturable elimination known to occur for this drug. | |
| 7131453 | The significance of fibronectin in cryoprecipitation in rheumatoid arthritis and other dis | 1982 Jul | Fibronectin, a glycoprotein produced by mesenchymal cells, was present in 11 of 16 plasma cryoprecipitates and 12 of 14 synovial fluid (SF) cryoprecipitates. In some SF cryoprecipitates it was the major protein component. Fibronectin levels were related to the development of serum turbidity in the cold and fibronectin was involved in the development of cold turbidity induced by some charged polysaccharides in plasma, serum, and SF. It is suggested that fibronectin, which is synthesized by vascular endothelial cells and synovial lining cells, is involved in the development of some cryoprecipitates in patients with rheumatoid arthritis and other diseases. | |
| 796938 | Ketoprofen in the treatment of rheumatoid arthritis. | 1976 | A double-blind cross-over trial of ketoprofen (200 mg daily) compared with placebo and aspirin (4 g daily) was carried out in 24 patients with rheumatoid arthritis. Ketoprofen was shown to be significantly more effective than placebo in terms of pain relief, degree and duration of morning stiffness, articular index and patients' assessment of improvement. No significant differences were noted between ketoprofen and aspirin, although side-effects were less with ketoprofen. | |
| 781229 | Fenoprofen calcium in steroid treated rheumatoid arthritis: efficacy, safety, and steroid- | 1976 | Twenty-one patients with active rheumatoid arthritis on maintenance corticosteroids were studied during a double-blind, crossover trial with fenoprofen. Fenoprofen showed significantly greater effect than did placebo on several subjective and objective measurements. In addition, patients were able to reduce their dose of corticosteroid to a level significantly lower than that during placebo periods. Though three patients dropped out of the study with gastrointestinal complaints while on fenoprofen, only one of these was believed to be drug-related. No serious adverse effects were encountered. | |
| 6747420 | The incidence of Dupuytren's disease in patients with rheumatoid arthritis. | 1984 Jun | Some conditions commonly associated with Dupuytren's disease are well-known. No attention has been paid to conditions with a significantly low incidence of Dupuytren's. A large number of patients with rheumatoid arthritis were studied, and were found to have a statistically significantly lower incidence of Dupuytren's disease, than was observed by the same clinicians in age, sex, matched controlled patients. | |
| 7035044 | Renal tubular dysfunction as a complication of gold therapy in patients with rheumatoid ar | 1982 Jan | Forty-five patients with uncomplicated rheumatoid arthritis and 45 control individuals were subjected to immunochemical investigation of the urinary excretion of renal tubular basement membrane antigen (TBM), renal tubular epithelial antigen (RTE), and beta-2-microglobulin. Tubular proteinuria occurred significantly more frequently in patients treated with gold salts than in those not treated (P less than 0.05). Large amounts of RTE and TBM were detected only in the urine of patients who received gold salt therapy. However, the amounts of these proteins in urine did no correlate with the total dose of gold. These results indicate that renal tubular damage frequently occurs in patients with rheumatoid arthritis who are treated with gold salts; the tests outlined are useful in detecting renal tubular disorders developing during gold salt therapy and have certain advantages over routine urinalysis. |